Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer
Yükleniyor...
Tarih
2018
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Indian Acad Sciences
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Targeted drug delivery approaches have been implementing significant therapeutic gain for cancer treatment since last decades. Aptamers are one of the mostly used and highly selective targeting agents for cancer cells. Herein, we address a nano-sized targeted drug delivery approach adorned with A-172 glioblastoma cell-line-specific single stranded DNA (ssDNA) aptamer in which the chemotherapeutic agent Doxorubicin (DOX) had been conjugated. DNA aptamer, GMT-3, was previously selected for specific recognition of glioblastoma and represented many advantageous characteristics for drug targeting purposes. Flow cytometry analysis proved the binding efficiency of the specific aptamer to tumour cell lines. Cell-type-specific toxicity of GMT-3:DOX complex was showed by XTT assay and terminated cytotoxic effects were screened for both target cell and a control breast cancer cell line. The result of this contribution demonstrated the potential utility of GMT-3 aptamer-mediated therapeutic drug transportation in the treatment of gliomas specifically. It was concluded that aptamer-mediated drug delivery can be applied successfully for clinical use.
Açıklama
WOS:000426370500010
PubMed:29485118
PubMed:29485118
Anahtar Kelimeler
A-172, Aptamer, Doxorubicin, Glioblastoma, GMT-3, XTT
Kaynak
WoS Q Değeri
Q2
Scopus Q Değeri
Q1
Cilt
43
Sayı
1
Künye
Bayraç, A. T., Akça, O. E., Eyidoğan, F. I., Öktem, H. A. (2018). Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer. Journal of Biosciences.
